Sistema de Salut de Catalunya
Institut Català de la Salut
[Fernández Montes A] Medical Oncology Department, Complexo Hospitalario Universitario de Ourense, Ourense, Spain. [Élez E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Vivancos A] Cancer Genomics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Martínez N] Medical Oncology Department, Hospital Universitario A Coruña, A Coruña, Spain. [González P] Medical Oncology Department, Hospital Universitario Álvaro Cunqueiro, Vigo, Spain. [Covela M] Medical Oncology Department, Hospital Universitario Lucus Augusti, Lugo, Spain
Vall d'Hebron Barcelona Hospital Campus
2022-09-06T12:27:43Z
2022-09-06T12:27:43Z
2022-06
Circulating tumor DNA; Liquid biopsy; Metastatic colorectal cancer
ADN tumoral circulante; Biopsia liquida; Cáncer colorrectal metastásico
ADN tumoral circulant; Biòpsia líquida; Càncer colorectal metastàtic
Purpose Some patients with histologically confirmed primary mCRC and mutated RAS reported undetectable RAS mutant clones in plasma after receiving anti-VEGF treatment. The aim was to prospectively assess it with its potential therapeutic implications. Methods RAS mutant genes in solid biopsy (before first-line treatment: FOLFOX/CAPOX + bevacizumab) were compared in liquid biopsy (before second-line treatment: panitumumab + FOLFIRI), using Idylla™ system. Discordant results between solid/liquid biopsies were assessed by the next-generation sequencing (NGS) test (solid/liquid biopsies). Results Twenty-three patients were assessed (seven had RAS mutant discrepancies between solid/liquid biopsies). The NGS test confirmed that 3/23 (13%) patients had undetectable RAS mutant clones in liquid biopsy and 3/23 (13%) presented discrepancies in solid biopsy (Idylla™ system vs. NGS test). Conclusion Thirteen percentage of patients had undetectable RAS mutant clones in liquid biopsy after first-line treatment. However, some discrepancies between solid and liquid biopsies have been observed. These results suggest a need to improve accuracy of RAS analyses, especially in solid biopsies.
This work was supported by Amgen S.A. Amgen did not have any role in study design; collection, analysis, and interpretation of data; writing the report; and the decision to submit the report for publication.
Article
Published version
English
Còlon - Càncer; Recte - Càncer; Clonatge molecular; DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms; ANATOMY::Cells::Cells, Cultured::Clone Cells; PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Variation::Mutation; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales; ANATOMÍA::células::células cultivadas::células clonales; FENÓMENOS Y PROCESOS::fenómenos genéticos::variación genética::mutación
Springer
Clinical and Translational Oncology;24
https://doi.org/10.1007/s12094-021-02767-7
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3437]
